Shares of Cipla Limited experienced a decline on Friday morning, dropping 1.27 percent to ₹1,289.30 on the NSE by 10:12 AM, despite the pharmaceutical company announcing a significant regulatory milestone in the United States. The stock opened at ₹1,295, reached a high of ₹1,295, and recorded a low of ₹1,254.10, with a total traded value surpassing ₹217 crore on volumes of 17.06 lakh shares. Buy orders comprised 54 percent of the total quantity, while sell orders accounted for 46 percent.
In a broader context, Cipla’s stock has underperformed, decreasing 14.36 percent year-to-date and 17.17 percent over the past year. In comparison, the Nifty 50 index has seen a loss of only 1.21 percent during the same timeframe. Cipla’s 52-week high is ₹1,673, which was achieved in October 2025, while its 52-week low was recorded at ₹1,165.70 on April 2 of this year.
Morgan Stanley has maintained an Underweight rating on Cipla’s stock, slightly raising its price target to ₹1,237 from ₹1,211. The brokerage estimates that the US FDA approval for generic Ventolin HFA could contribute $130 million in sales potential for FY27, which may result in a 4 percent boost to the company’s earnings per share (EPS). While the approval is expected to mitigate the decline in Lanreotide sales and enhance Cipla’s respiratory portfolio, the firm has noted that the company’s continued reliance on its pipeline execution represents a key risk.
Cipla USA Inc. received final USFDA approval for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation, marking it as the first AB-rated generic version of GlaxoSmithKline’s Ventolin HFA. This product aims to tap into a US albuterol market valued at approximately $1.5 billion and is projected for launch in the first half of FY2026-27. It will be produced at Cipla’s specialized inhalation facility located in Fall River, Massachusetts.
Published on April 24, 2026.
